echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New cutting-edge to improve the safety and durability of CAR-T therapy receives 250 million U.S. dollars from Blackstone

    New cutting-edge to improve the safety and durability of CAR-T therapy receives 250 million U.S. dollars from Blackstone

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On November 8, 2021, Autolus Therapeutics announced that it has reached a strategic cooperation and financing agreement with Blackstone Life Sciences
    According to the terms of the agreement, Blackstone will provide up to US$250 million to support Autolus in advancing the clinical research and commercialization of obecabtagene autoleucel (obe-cel), an in-development CAR-T cell therapy targeting CD19, and development for the treatment of B cell malignancies The next generation of tumor products

    Obe-cel's durability and good safety characteristics demonstrated in previous studies support its potential as a single-agent first-line treatment for adult acute lymphoblastic leukemia (ALL)


    Obe-cel aims to overcome the limitations of current CAR-T cell therapy in terms of clinical activity and safety
    Its uniqueness is that the designed chimeric antigen receptor has a fast off-rate after binding to CD19, which can minimize the over-activation of T cells and reduce toxic and side effects at the same time.
    T cell exhaustion is not prone to occur, so as to improve the durability of CAR-T therapy

    Obe-cel is currently being evaluated in a pivotal Phase 1b/2 clinical trial for the treatment of adult patients with acute lymphoblastic leukemia

    In addition, obe-cel is also being evaluated in a phase 1 clinical trial for the treatment of B-cell non-Hodgkin's lymphoma (B-NHL)


    In the trial data released in June this year, obe-cel achieved a 100% complete remission rate in a cohort of patients for the treatment of indolent B-cell non-Hodgkin's lymphoma (iNHL)
    At the same time, in the treatment of patients with acute lymphoblastic leukemia, 85% of patients achieved minimal residual disease (MRD) negative complete remission after 1 month of treatment, and event-free survival rates after 12 months and 24 months of treatment (EFS) is 50.
    2%, showing the durability of complete remission


    ▲Obe-cel's performance in the treatment of ALL patients (picture source: Autolus official website)

    Reference materials:

    [1] Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform.
    Retrieved November 8, 2021, from https://autolus.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.